Imidazole‐thiadiazole hybrids: A multitarget de novo drug design approach, in vitro evaluation, ADME/T, and in silico studies
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Maryam Maqbool und 8 weiteren Autor:innen. Beteiligte Einrichtung: H. E. J. Research, Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan. Hauptthemen laut MEDLINE: Thiadiazoles, Imidazoles, Drug Design, Antioxidants. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Pakistan Academy of Sciences.
Abstract (Originalsprache)
A library of imidazole‐thiadiazole compounds ( 1–24 ) was synthesized to explore their therapeutic applications. The compounds were subjected to meticulous in vitro evaluation against α ‐glucosidase, α ‐amylase, acetylcholinesterase (AChE), and butylcholinesterase (BChE) enzymes. Compounds were also investigated for antioxidant activities using cupric reducing antioxidant capacity (CUPRAC), ferric reducing antioxidant power (FRAP), and 1,1‐diphenyl‐2‐picrylhydrazyl (DPPH) assays. Derivatives 5–7 , 9–11 , 18 , and 19 displayed potent inhibitory activities with IC 50 values of 1.4 ± 0.01 to 13.6 ± 0.01 and 0.9 ± 0.01 to 12.8 ± 0.02 µM against α ‐glucosidase, and α ‐amylase enzymes, respectively, compared to the standard acarbose (IC 50 = 14.8 ± 0.01 µM). Compounds 11–13 , 16 , 20 , and 21 exhibited potent activity IC 50 = 8.6 ± 0.02 to 34.7 ± 0.03 µM against AChE enzyme, compared to donepezil chloride (IC 50 = 39.2 ± 0.05 µM). Compound 21 demonstrated comparable inhibition IC 50 = 45.1 ± 0.09 µM against BChE, compared to donepezil chloride (IC 50 = 44.2 ± 0.05 µM). All compounds also demonstrated excellent antioxidant activities via CUPRAC, FRAP, and DPPH methods. Complementing the experimental studies, extensive kinetics, ADME/T, and molecular docking analysis were also conducted to unravel the pharmacokinetics and safety profiles of the designed compounds. These studies supported the experimental findings and facilitated the prioritization of hit candidates for subsequent stages of drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- H. E. J. Research, Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
- Pakistan Academy of Sciences, Islamabad, Pakistan.
- Department of Chemistry, Recep Tayyip Erdogan University, Rize, Turkey.
- Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
- Department of Clinical Pharmacy, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
ORCID-Profile: Khalid M Khan
Förderung
- Pakistan Academy of Sciences
Zitieren
APA
Maqbool, M., Solangi, M., Khan, K. M., Özil, M., Baltaş, N., Salar, U., Tariq, S. S., Haq, Z. U., & Taha, M. (2024). Imidazole‐thiadiazole hybrids: A multitarget de novo drug design approach, in vitro evaluation, ADME/T, and in silico studies. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400325
Vancouver
Maqbool M, Solangi M, Khan KM, Özil M, Baltaş N, Salar U, et al. Imidazole‐thiadiazole hybrids: A multitarget de novo drug design approach, in vitro evaluation, ADME/T, and in silico studies. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400325
BibTeX
@article{Maqbool2024,
author = {Maqbool, Maryam and Solangi, Mehwish and Khan, Khalid M and Özil, Musa and Baltaş, Nimet and Salar, Uzma and Tariq, Syeda S and Haq, Zaheer Ul and Taha, Muhammad},
title = {Imidazole‐thiadiazole hybrids: A multitarget de novo drug design approach, in vitro evaluation, ADME/T, and in silico studies},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400325}
}
EUVIMED